Chester County News and Community Website
WILMINGTON, DE — AstraZeneca (LSE/STO/NYSE: AZN) reported Phase III trial results showing that a combination of its immunotherapy drugs IMFINZI and IMJUDO with lenvatinib and transarterial chemoembolization (TACE) significantly delayed …
AstraZeneca Liver Cancer Regimen Extends Progression-Free Survival in Phase III Trial Read More
WILMINGTON, DE — AstraZeneca has secured U.S. regulatory approval for IMFINZI (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) therapy for adults with previously untreated high-risk non-muscle-invasive bladder cancer, expanding the …
AstraZeneca Wins FDA Approval for IMFINZI in Early Bladder Cancer Read More WILMINGTON, DE — AstraZeneca and Daiichi Sankyo have secured U.S. approval for DATROWAY as a first-line treatment for certain patients with metastatic triple-negative breast cancer, expanding treatment options in a …
AstraZeneca, Daiichi Sankyo Win FDA Approval for DATROWAY in Breast Cancer Read More WILMINGTON, DE — AstraZeneca said new Phase III cancer and rare disease data presented at the American Society of Clinical Oncology annual meeting could strengthen the company’s position in several …
AstraZeneca Highlights Late-Stage Cancer, Rare Disease Data at ASCO Read More WILMINGTON, DE — AstraZeneca received U.S. regulatory approval for BAXFENDY (baxdrostat), a new treatment for adults with uncontrolled hypertension, marking the first new drug class for the condition in years …
FDA Clears AstraZeneca Blood Pressure Drug, Expanding Options for Uncontrolled Hypertension Read More WILMINGTON, DE — AstraZeneca (LSE/STO/NYSE: AZN) reported positive Phase III trial results showing its immunotherapy IMFINZI combined with enfortumab vedotin improved survival outcomes for certain muscle-invasive bladder cancer patients unable …
AstraZeneca Trial Extends Survival in Bladder Cancer Study Read More WILMINGTON, DE — An advisory committee to the U.S. Food and Drug Administration voted 7-1, with one abstention, that AstraZeneca’s TRUQAP combination therapy demonstrated a favorable benefit-risk profile for patients …
FDA Panel Backs AstraZeneca Prostate Cancer Drug Combo Read More WILMINGTON, DE — AstraZeneca said the SAPHNELO Pen has received approval from the U.S. Food and Drug Administration for self-administration in adults with systemic lupus erythematosus receiving standard therapy.
FDA Approves AstraZeneca Lupus Autoinjector Treatment Read More WILMINGTON, DE — AstraZeneca reported that its experimental drug tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease in a Phase III trial.
AstraZeneca Drug Reduces COPD Exacerbations in Phase III Trial Read More WILMINGTON, DE — AstraZeneca reported that its drug combination including IMFINZI and IMJUDO, used with lenvatinib and transarterial chemoembolization, improved progression-free survival in patients with unresectable liver cancer eligible for …
AstraZeneca Trial Shows Improved Outcomes in Liver Cancer Study Read More